A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145

Trial Profile

A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Adverse reactions
  • Acronyms OSLER-2; PROFICIO
  • Sponsors Amgen
  • Most Recent Events

    • 29 Aug 2016 Results of pooled subgroup analysis from OSLER-1 and OSLER-2 were presented at the European Society of Cardiology (ESC) Congress 2016, according to an Amgen media release.
    • 01 Oct 2015 Planned End Date changed from 1 May 2018 to 1 Aug 2018, as reported by ClinicalTrials.gov
    • 01 Oct 2015 Planned primary completion date changed from 1 May 2018 to 1 Aug 2018, as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top